Cindy Martinez
General Practice · Hormigueros, PRNPI 1700947009
Payments from drug & device makers
Across 1,108 payments — averaging $2897.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1.2M
- Avanir Pharmaceuticals, Inc.$855K
- Eisai Inc.$588K
- Esperion Therapeutics, Inc.$371K
- Sanofi US Services Inc.$114K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$57K
- plus $68K from 5 others
Across 1 payment — averaging $213.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$214
What the payments were for
- Food & beverage$258100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 106 | $1,156,297 |
| Avanir Pharmaceuticals, Inc. | 42 | $855,014 |
| Eisai Inc. | 327 | $588,111 |
| Esperion Therapeutics, Inc. | 597 | $371,374 |
| Sanofi US Services Inc. | 15 | $114,060 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $57,020 |
| AstraZeneca | 1 | $51,314 |
| H. Lundbeck A S | 13 | $16,893 |
| Amgen | 1 | $124 |
| Kyowa Kirin, Inc. | 1 | $115 |
| IBSA Pharma Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,210,340 in reported general payments places this provider in the 95th percentile of 3,586 general practice providers in Puerto Rico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VascepaIcosapent Ethyl | 21 | $6,689 |
| Rosuvastatin Calcium | 32 | $760 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 15 | $586 |
| Atorvastatin Calcium | 51 | $459 |
| Diclofenac Sodium | 12 | $388 |
| Ketoconazole | 12 | $313 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $274 |
| Clarithromycin | 12 | $263 |
| Losartan Potassium | 24 | $245 |
| Omeprazole | 15 | $239 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 12 | $203 |
| Levothyroxine Sodium | 40 | $138 |
| Gabapentin | 23 | $115 |
| Amlodipine Besylate | 19 | $112 |
| Pantoprazole Sodium | 19 | $110 |
Paid to pharmacies, not to this prescriber.
Other general practice in Hormigueros
- Guillermo Pagan CaloHormigueros$40K
- Gregorio Cortes-MaisonetSan Juan$12.8M
- Barbara Orozco PerezCanovanas$5.1M
- Jesus Rodriguez RodriguezPonce$4.9M
- Luis PaganDorado$3.3M
- Gustavo AlbizuMorovis$3.1M
- Elham GhorbaniDorado$1.2M
- Victor MorenoMaunabo$903K
- Grisselle Ortiz RiveraMorovis$715K
- Elba PerezTrujillo Alto$651K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.